TGFB2 and pancreatic neoplasm: The novel cis-pQTL for TGF-β2 was then tested for validation in independent external cohorts of castration-resistant prostate cancer (CALGB 90401) and advanced pancreatic cancer patients (CALGB 80303) [9–13].